New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

Though the vaccine’s sales rose consistently till 2022, it started witnessing sluggish sales from 2024. Sales of the vaccine ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease.

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of adults aged 18 to 59 years at increased risk for disease.

In the US in October 2024, the FDA approved Abrysvo for the prevention of lower respiratory tract disease caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD ...

The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy ...

Findings from this self-controlled case series showed an increased risk of GBS during the 42 days following vaccination with Abrysvo (9 excess cases per million doses; incidence rate ratio [GBS ...

Abrysvo has been approved for the prevention of lower respiratory tract disease caused by RSV in all individuals 60 years of age and older, ... The FDA Issues a New Definition for Food Labeling.

Moving forward, the FDA has required and approved safety labeling changes to the prescribing information for Abrysvo and Arexvy based on the totality of data from clinical trials, reports to VAERS, ...

The FDA has mandated updated safety labeling for two respiratory syncytial virus vaccines, Pfizer’s Abrysvo and GlaxoSmithKline’s Arexvy, following the identification of an increased risk of ...